Get to know our clinical trials
Phase I/II study of STK-012 as monotherapy and in combination therapy in solid tumors.
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO DETERMINE WHETHER STK-012 ADMINISTERED TOGETHER WITH STANDARD-OF-CARE TREATMENT IS MORE EFFECTIVE IN TREATING CANCER THAN STANDARD-OF-CARE TREATMENT ALONE IN PATIENTS WITH LUNG CANCER. STK-012 IS A NEW INVESTIGATIONAL DRUG BEING STUDIED BY THE SPONSOR.
Technical Summary
- PHASE I/II STUDY TO EVALUATE STK-012 AS MONOTHERAPY AND IN COMBINATION THERAPY IN SUBJECTS WITH ADVANCED NSCLC AS FIRST-LINE TREATMENT AND OTHER SELECTED INDICATIONS.
- Code EudraCT: 2025-522632-14-00
- Protocol number: STK-012-101
- Promoter: Synthekine, Inc.
- Molecule/Drug: STK-012
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.